| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.350 | Biomarker | group | LHGDN | The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. | 17986287 | 2008 | ||||
|
0.350 | Biomarker | group | CTD_human | Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. | 17592021 | 2007 | ||||
|
0.350 | GeneticVariation | group | LHGDN | Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. | 17826473 | 2007 | ||||
|
0.350 | Biomarker | group | CTD_human | Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. | 16859836 | 2006 | ||||
|
0.350 | Biomarker | group | CTD_human | Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. | 16998812 | 2006 | ||||
|
0.350 | Biomarker | group | CTD_human | Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. | 16424004 | 2006 | ||||
|
0.350 | GeneticVariation | group | LHGDN | [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men]. | 16519145 | 2006 | ||||
|
0.350 | Biomarker | group | BEFREE | To our knowledge, this is the first example of an antihormonal agent (an inhibitor of androgen synthesis (CYP17 inhibitor)/antiandrogen) that is significantly more effective than castration in suppression of androgen-dependent prostate tumor growth. | 15828836 | 2005 | ||||
|
0.350 | Biomarker | group | CTD_human | Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. | 15538743 | 2005 | ||||
|
0.350 | GeneticVariation | group | LHGDN | Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. | 15477877 | 2004 |